No description available.

Ischemic preconditioning is an endogenous cardioprotective mechanism in which short periods of ischemia and reperfusion provide protection when given before a subsequent ischemic event. Early mechanistic studies showed ATP-sensitive potassium (KATP) channels to play an important role in ischemic preconditioning. KATP channels link intracellular energy metabolism to membrane excitability and contractility. It is thought that KATP channels provide a cardioprotective role during ischemia by inducing action potential shortening, reducing an excessive Ca^2+ influx, and by preventing arrhythmias. However, the mechanisms by which KATP channels protect during ischemic preconditioning are not known. In this study, we investigated a novel potential mechanism in which alterations in subcellular KATP channel trafficking during ischemia and ischemic preconditioning may result in altered levels of surface channel density, and therefore, a greater degree of cardioprotection. In the optimization of our experiments, we compared various antibodies for their specificity and sensitivity for channel subunit detection in immunoblotting. In addition, we examined the effects of varying salt concentrations during tissue homogenization in order to determine the optimal conditions for protein isolation. Furthermore, we examined the effect of heating the samples prior to SDS-PAGE for improved detection of channel proteins by immunoblotting. The subcellular trafficking of some membrane proteins is altered by ischemia. For example, the glucose transporter, Glut4, translocates from endosomal compartments to the sarcolemma (Sun, Nguyen, DeGrado, Schwaiger, & Brosius, 1994). Conflicting data exists regarding the effects of ischemia on KATP channel subcellular trafficking and the regulation of KATP channel surface density (Edwards et al., 2009 and Bao, Hadjiolova, Coetzee, & Rindler, 2011). We therefore, sought to test our hypothesis that KATP channels are internalized from the surface of cardiomyocytes to endosomal compartments during ischemia, and this internalization can be reduced and/or reversed by ischemic preconditioning. We subjected isolated Langendorff-perfused mouse hearts to ischemia, reperfusion, or ischemic preconditioning events and measured the density of KATP channels in the sarcolemmal and endosomal compartments. We also determined the degree of injury by staining heart slices with triphenyltetrazolium chloride and compared infarct sizes between hearts subjected to ischemia and ischemic preconditioning. Our data demonstrated that KATP channels are, in fact, internalized during ischemia and that reperfusion led to a slow recovery of surface KATP channel density. Interestingly, ischemic preconditioning reduced the size of infarcts induced by ischemia and also prevented the ischemia-induced decrease of KATP channel surface density, thereby, contributing to cardioprotection.

Resistin is an adipocytokine derived from adipose tissue. Studies showed that resistin is not only related to insulin resistance, but also possibly an important factor related to activating of inflammation and atherosclerosis. It influences the endothelial cells and the function of vessel. To investigate whether or not resistin play a role in the metabolic syndrome and ischemic stroke. we examined the plasma resistin concentrations as well as the 3¡¦ untranslated region +62 G/A polymorphism of resistin gene in a Taiwan population. In the first part of this study, 112 patients with ischemic cerebral vascular disease and 110 healthy subjects were included and analyses of demographic and biochemical parameter, high sensitive C-reactive protein and plasma resistin concentration measurements were performed. In the second part, 594 patients with ischemic cerebral vascular disease and 799 healthy control were examined for resistin 3¡¦ untranslated region +62 G/A polymorphism. Resistin concentration was analyzed by EIA method, and resistin 3¡¦ untranslated region +62 G/A polymorphism was done by PCR and RFLP. The mean plasma resistin concentration of 112 patients with ischemic cerebral vascular disease was significantly lower than that of the 110 controls (32 ¡Ó 59.7 ng/ml and 55.7 ¡Ó 82.5 ng/ml, p < 0.001).When the concentration of resistin was divided into 4 groups and analyzed as continuous variable, it was found that decreased plasma resistin concentration is associated with increased risk of ischemic cerebral vascular disease. After the multiple adjustment by logistic analysis, the adds ratio for the first, second and third quadrate were 7.8, 5.0 and 0.1, respectively). The genotype analysis of 594 patients with ischemic cerebral vascular disease and 799 healthy controls show that the resistin genotype was related statistically to the risk of ischemic stroke. In multiple regression analysis, resistin 3¡¦ untranslated region +62 G/A polymorphism was significantly associated with diastolic blood pressure (GA + AA : GG = 142.2 ¡Ó 19.2 : 139.3 ¡Ó 20.7 mmHg, p = 0.044) and fasting plasma sugar (GA + AA : GG : 83.4 ¡Ó 13.1 : 81.1 ¡Ó 13.1 mg/dl , p = 0.005). Our results indicated that resistin may be related to metabolic syndrome and ischemic cerebral vascular disease and possibly play a role in the development of atherosclerosis.

Background/Objectives: Gaps in care due to the movement of patients between health settings and/or practitioners, known as transitions of care (TOC), may contribute to second stroke or TIA events. The elements that impact TOC in the stroke/TIA population have not been fully elucidated. The purpose of this study is to identify key elements of a Doctor of Nursing Practice-led TOC model that could be used to develop and evaluate a TOC program for the stroke/TIA population. Design: A descriptive study was performed to 1) identify elements that may affect transitions of care using a stroke database and post-discharge phone surveys and 2) based on information from Aim 1, propose a DNP-led TOC model specific to the stroke/TIA. Setting: An urban primary stroke center in the southwest United States. Participants: All patients in the GWTG®-stroke database from May 1 - December 31st, 2012 and patients who consented at discharge from the stroke unit following a stroke or TIA. Measurements: Patient demographics including: length of stay (LOS), age, race, ethnicity, comorbidities, insurance, discharge status, thirty-day readmission rate, and follow up survey. Results: Patient data (n=276) from GWTG®-stroke database was obtained. Average LOS was 7.81 +/- 11.15 days. The majority of patients were greater than age 65 (59%); 53% relied on Medicare support; those age 50-59 (21%) were most likely to be uninsured (47%). Fifty-one percent were discharged directly home, 48% of those were referred to outpatient rehab services. Two-thirds received rehabilitation services during hospitalization. Eight patients experienced a subsequent hospital readmission; two of those had a repeat stroke event. Although patients reported understanding their discharge instructions, their perception of ongoing care was poor. Conclusion: Key elements of a TOC model specific to the stroke and TIA patient population could include: patient surveillance, comprehensive care planning, follow-up, stroke education and point of contact. Advanced practice nurses have been successful in leading such programs, and a DNP-led model providing continuity of care would support the transition of an effective model into clinical practice.

El texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado. / Background: Various randomized-controlled clinical trials (RCTs) have investigated the neuroprotective role of minocycline in acute ischemic stroke (AIS) or acute intracerebral hemorrhage (ICH) patients. We sought to consolidate and investigate the efficacy and safety of minocycline in patients with acute stroke. Methods: Literature search spanned through November 30, 2017 across major databases to identify all RCTs that reported following efficacy outcomes among acute stroke patients treated with minocycline vs. placebo: National Institute of Health Stroke Scale (NIHSS), Barthel Index (BI), and modified Rankin Scale (mRS) scores. Additional safety, neuroimaging and biochemical endpoints were extracted. We pooled mean differences (MD) and risk ratios (RR) from RCTs using random-effects models. Results: We identified 7 RCTs comprising a total of 426 patients. Of these, additional unpublished data was obtained on contacting corresponding authors of 5 RCTs. In pooled analysis, minocycline demonstrated a favorable trend towards 3-month functional independence (mRS-scores of 0–2) (RR = 1.31; 95% CI 0.98–1.74, p = 0.06) and 3-month BI (MD = 6.92; 95% CI − 0.92, 14.75; p = 0.08). In AIS subgroup, minocycline was associated with higher rates of 3-month mRS-scores of 0–2 (RR = 1.59; 95% CI 1.19–2.12, p = 0.002; I2 = 58%) and 3-month BI (MD = 12.37; 95% CI 5.60, 19.14, p = 0.0003; I2 = 47%), whereas reduced the 3-month NIHSS (MD − 2.84; 95% CI − 5.55, − 0.13; p = 0.04; I2 = 86%). Minocycline administration was not associated with an increased risk of mortality, recurrent stroke, myocardial infarction and hemorrhagic conversion. Conclusions: Although data is limited, minocycline demonstrated efficacy and seems a promising neuroprotective agent in acute stroke patients, especially in AIS subgroup. Further RCTs are needed to evaluate the efficacy and safety of minocycline among ICH patients. / Revisión por pares / Revisión por pares

BACKGROUND: Under the current treatment guidelines for acute ischemic stroke, intravenous alteplase may be used within 3-4.5 hours of symptom recognition or in cases of unknown onset if there is a small lesion on diffusion weighted imaging without increased signal on FLAIR sequence MRI. We seek to determine whether patients with lacunar strokes greater than 4.5 hours post onset with a DWI-FLAIR mismatch on imaging will benefit from thrombolysis with intravenous alteplase. METHODS: We will conduct a multicenter, randomized, double-blinded, placebo-controlled trial of patients presenting with acute ischemic stroke within 4.5 to 6 hours of symptom onset with DWI-FLAIR mismatch and without a large vessel occlusion. A target of 682 patients will be randomized to receive IV alteplase or placebo. The primary outcome is a favorable functional status as defined by a score of 0 or 1 on the modified Rankin scale (mRS) at 90 days. The secondary outcome is ordinal score on the modified Rankin scale at 90 days. The primary safety end points will be symptomatic intracranial hemorrhage (sICH) and death CONCLUSIONS: If intravenous (IV) alteplase is found to be an effective and safe treatment for lacunar stroke with DWI-FLAIR mismatch >4.5 hours from onset, these patients could have significantly reduced morbidity and improved long-term outcomes.

Sarcolemmal blebbing and rupture are prominent features of irreversible ischemic myocardial injury. Dystrophin and spectrin are sarcolemmal structural proteins. Dystrophin finks the transmembrane dystroglycan complex and extracellular laminin receptors to intracellular F-actin. Spectrin forms the backbone of the membrane skeleton confering an elastic modulus to the sarcolemmal membrane. An ischemic loss of membrane dystrophin and spectrin, in ischemically pelleted rabbit cardiomyocytes or in vivo 30-45 rain permanently ischemic. LAD-ligated hearts, was detected by immunofluorescence with monoclonal antibodies. Western blots of light and heavy microsomal vesicles and Triton-extracted membrane fractions from ischemic myocytes demonstrated a rapid loss of dystrophin coincident with sub-sarcolemmal bleb formation, subsequent to a hypotonic challenge. The loss of spectrin from purified sarcolemma of autolysed rabbit heart, and both isolated membrane vesicles and Triton solubilized membrane fractions of ischemic cardiomyocytes correlated linearly with the onset of osmotic fragility as assessed by membrane rupture, subsequent to a hypotonic challenge. In contrast to the ischemic loss of dystrophin and spectrin from the membrane, the dystrophin-associated proteins. α-sarcoglycan and β-dystroglycan and the integral membrane protein, sodium-calcium exchanger, were maintained in the membrane fraction of ischemic cells as compared to oxygenated cells. Preconditioning protected cells, but did not significantly alter ischemic dystrophin or spectrin translocation. This previously unrecognized loss of sarcolemmal dystrophin and spectrin may be the molecular basis for sub-sarcolemmal bleb formation and membrane fragility during the transition from reversible to irreversible ischemic myocardial injury.

CADASIL est une forme héréditaire, autosomique dominante, de maladie des petits vaisseaux cérébraux dans laquelle surviennent précocement des lésions de la substance blanche cérébrale qui progressent avec le temps, mais dont la nature histopathologique demeure très mal connue. La maladie est causée par des mutations très stéréotypées du récepteur Notch3. Une des signatures de CADASIL est la présence, dans les vaisseaux, d’une accumulation du domaine extracellulaire de NOTCH3 (Notch3ECD). Un faisceau d’arguments suggère que le processus pathogène de CADASIL résulte d’un effet toxique de ces dépôts de Notch3ECD, qui passerait par l’accumulation avec le NOTCH3ECD d’autres protéines de la matrice extracellulaire. Il a cependant été montré que des mutations CADASIL affectent les capacités de signalisation du récepteur, de manière constitutive ou avec le temps, ce qui a conduit à formuler l’hypothèse qu’une perte de fonction Notch3 pourrait également constituer un déterminant important du processus pathogène.Nous avons réalisé une analyse détaillée des lésions de la substance blanche dans un modèle murin de la maladie CADASIL obtenu par surexpression d’un allèle Notch3 avec la mutation R169C / R170C, qui en récapitule les stades précliniques (TgPACNotch3R169C). Ceci a permis de mettre en évidence aux stades précoces un oedème intramyélinique associé à une dégradation / décompaction de la myéline détectable en immunohistochimie dès l’âge de 6 mois. L’analyse de l’intégrité axonale au sein des lésions de la myéline suggère une perte secondaire. Une méthode de quantification semi-automatisée des débris myélinique a été élaborée.Nous avons ensuite testé l’hypothèse qu’une perte de fonction Notch3 pourrait constituer un déterminant majeur dans le processus pathogène de CADASIL. Nous avons pour cela identifié un set de gènes dont l’expression est sensible à la quantité de Notch3, capable de détecter une diminution de moitié de la dose de Notch3. La mesure de l’expression de ces gènes chez des souris Knock-in pour la mutation R170C, hétérozygotes ou homozygotes, a montré que l’activité Notch3 n’était pas diminuée dans ce modèle. Nous avons ensuite étudié l’impact de la suppression des copies endogènes de Notch3 sur les lésions de la substance blanche chez les souris TgPACNotch3R169C, qui n’apparaissent pas aggravées. Ces résultats plaident contre un effet hypomorphe commun à toutes les mutations CADASIL et suggèrent que les lésions de la substance blanche ne sont pas secondaires à un tel effet.Nous avons enfin étudié le rôle pathogène de l’excès de TIMP3 et vitronectine, deux protéines dont il a été démontré qu’elles s’accumulent précocement avec le NOTCH3ECD. En utilisant des approches d’interaction génétique (diminution et/ou augmentation de la quantité de TIMP3 et vitronectine chez les souris TgPACNotch3R169C), nous avons observé un effet différent de l’excès des deux protéines sur les anomalies de la réactivité cérébrovasculaire et celles de la substance blanche. En effet, la réduction de la quantité de vitronectine limite les lésions de la substance blanche sans effet sur la réactivité cérébrovasculaire alors que la réduction de TIMP3 corrige les anomalies vasculaires fonctionnelles sans effet sur la substance blanche. Ces résultats apportent la preuve de concept du rôle pathogène de l’accumulation des protéines TIMP3 et vitronectine dans le processus pathogène de CADASIL et remettent en question les dogmes faisant de l’hypoperfusion le facteur promoteur des lésions de la substance blanche dans la maladie. / CADASIL is an autosomal dominant, hereditary, small vessel disease of the brain causing early and progressive white matter lesions. The histopathological characteristics of these lesions remain poorly known. The disease is caused by stereotyped mutations in the gene coding for the NOTCH3 receptor. One of CADASIL hallmarks is the presence in vessels of an abnormal accumulation of NOTCH3 extracellular domain (NOTCH3ECD). Data suggest that CADASIL pathophysiological process may be caused by a toxic effect resulting from NOTCH3ECD deposits, due to an abnormal recruitment of other extracellular matrix components. However, it has been shown that CADASIL mutations differentially affect Notch3 signaling, constitutively or progressively. The latter observations led scientists to propose the hypothesis that Notch3 loss of function may play an important role in CADASIL pathogenesis.We conducted a detailed white matter analysis in a CADASIL mouse model that overexpresses a Notch3 allele with the R169C/R170C mutation and that recapitulates the preclinical stages of the disease (TgPACNotch3R169C). In this model, we observed intramyelinic edema associated with myelin degradation / decompaction detectable by immunochemistry in the brain of mice as young as 6 months of age. Axonal integrity analysis in myelin lesions suggested that axonal loss may appear secondarily. A semi-quantitative method for the quantification of myelin debris has been developed.Next, we tested the hypothesis that Notch3 loss of function might play a key role in CADASIL pathophysiology. We first identified a set of genes that are sensitive to a reduction in Notch3 dosage by half. Quantification of these genes expression in both heterozygous and homozygous mice Knock-in for the R170C mutation showed that Notch3 activity was not lowered in this model. In addition, we analyzed the effect of a suppression of endogenous Notch3 copies on white matter lesions observed in TgPACNotch3R169C mice and observed no worsening of these lesions. Together these results suggest that hypomorphism is not a feature common to all CADASIL mutations, and that white matter lesions in CADASIL do no result from Notch3 loss of function.Finally, we studied the pathogenic effect of Timp3 and vitronectine accumulation, both proteins having been shown to accumulate with NOTCH3ECD early in the course of the disease. By the use of genetic interaction approaches (lowering and increase in Timp3 and vitronectine in TgPACNotch3R169C mice), we observed differential effects of the proteins on white matter lesions and cerebrovascular reactivity impairment. Indeed, vitronectine lowering improves white matter lesions without any effect on cerebrovascular reactivity while Timp3 diminution restores cerebrovascular reactivity without any effect on white matter lesions. These results provide proof of concept for the implication of TIMP3 and vitronectin excess in CADASIL pathogenesis and questions the dogma that make hypoperfusion the main determinant of white matter lesions in CADASIL.

Indiana University-Purdue University Indianapolis (IUPUI) / Hydrodynamic delivery is a powerful tool that allows delivery of macromolecules to the kidney culminating in gene expression. This finding is important in the fight against kidney disease. Current therapy for kidney injury, specifically acute kidney injury, is lacking. Supportive care in the form of IV fluids and medications aimed at restoring Glomerular Filtration Rate (GFR) and urine output are currently used. However, even with these treatments, prognoses of patients diagnosed with this disease remains poor. We believe that hydrodynamic delivery provides a mechanism that can be used to reverse and prevent AKI. Hydrodynamic delivery following ischemic injuries leads to reductions in serum creatinine and infiltrating mononuclear cells, as well as increased renal blood flow and survival. These changes are due to reductions in vascular congestion and inflammation typically seen following injury. To determine the underlying mechanisms of gene delivery preventing AKI, we used candidate genes identified in a proteomic screen on kidneys that recovered from AKI. We selected Isocitrate Dehydrogenase II (IDH2) and Sulfotransferase 1C2 (SULT1C2) for study and found that delivery prior to injury prevents serum creatinine increase and reduces cell death. We found that gene delivery of IDH2 prevents a glycolytic shift typically seen following ischemic injuries. The mechanism underlying the prevention of this shift are seen in increased ATP stores and spare respiratory capacity allowing the cell to remain in an oxidative state. Additionally, we show that SULT1C2 post-translationally modifies the mitochondria membrane, increasing oxidative phosphorylation providing the cell with additional energy needed in times of oxidative stress. These candidate genes allow cells to remain in an oxidative state preventing the activation of cell death pathways typically activated following injury, thereby preserving normal kidney function.

No description available.